What is the 13F Pro Quality Score for IMUX?

13F Pro ranks IMMUNIC, INC. (IMUX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IMUX's current score at https://13fpro.ai/research/IMUX (free sign-up required for the full ranking).

Which hedge funds own the most IMUX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IMUX include abrdn plc, BVF /IL, Avidity Partners Management. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/IMUX as soon as new 13F filings post.

Where does 13F Pro source IMUX data?

All IMMUNIC, INC. fundamentals and ownership data come directly from SEC EDGAR. IMMUNIC, INC. files with the SEC under CIK 1280776. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IMUX in?

IMMUNIC, INC. (IMUX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IMUX research updated on 13F Pro?

IMUX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IMMUNIC, INC.(IMUX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1280776 IMUX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

IMUX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for IMMUNIC, INC. (IMUX), a Healthcare sector company. IMUX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), IMMUNIC, INC. reports net income of $-32.6M, free cash flow of $-17.3M. Top institutional holders of IMUX by reported 13-F value include abrdn plc, BVF /IL, Avidity Partners Management, based on the most recent SEC filings. IMUX trades on the Nasdaq exchange and files with the SEC under CIK 1280776. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMUX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IMMUNIC, INC. directly from SEC EDGAR.

Net Income

Q1 2026

$-32.6M

Free Cash Flow

Q1 2026

$-17.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+3.3% YoY

$-97.2MFY 2025

FY21 $-92.9MFY22 $-120.4MFY24 $-100.5MFY25 $-97.2M

Operating Income

-5.3% YoY

$-103.2MFY 2025

FY21 $-91.7MFY22 $-119.5MFY24 $-98.1MFY25 $-103.2M

EPS (Diluted)

+38.0% YoY

$-0.62FY 2025

FY21 $-3.93FY22 $-3.78FY24 $-1.00FY25 $-0.62

Total Assets

-41.1% YoY

$24.1MFY 2025

FY21 $139.1MFY22 $127.8MFY24 $40.9MFY25 $24.1M

Op. Cash Flow

-1.2% YoY

$-85.8MFY 2025

FY21 $-83.2MFY22 $-65.1MFY24 $-84.8MFY25 $-85.8M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Net Income	$-97.2M +3.3%	$-100.5M +16.5%	$-120.4M -29.5%	$-92.9M -111.2%	$-44.0M -26.0%	$-34.9M
Operating Income	$-103.2M -5.3%	$-98.1M +17.9%	$-119.5M -30.4%	$-91.7M -87.2%	$-49.0M -32.2%	$-37.0M
EPS (Diluted)	$-0.62 +38.0%	$-1.00 +73.5%	$-3.78 +3.8%	$-3.93 -39.9%	$-2.81	—
Total Assets	$24.1M -41.1%	$40.9M -68.0%	$127.8M -8.2%	$139.1M -17.1%	$167.9M +154.5%	$66.0M
Operating Cash Flow	$-85.8M -1.2%	$-84.8M -30.1%	$-65.1M +21.7%	$-83.2M -80.5%	$-46.1M -61.6%	$-28.5M

AI Insight: IMUX Financial Trends

IMUX burning cash with accelerating losses in Q1 2026 despite equity injection; clinical-stage biotech with no revenue visibility.

• Net income deteriorated to –$33M in Q1 2026 from –$19M in Q4 2025; operating income widened to –$33M.

• Equity swung from –$7M (Q4 2025) to +$151M (Q1 2026), indicating substantial capital raise to extend runway.

• Operating cash flow improved to –$17M (Q1 2026) from –$20M to –$25M range prior four quarters.

⚠ Operating losses accelerating despite improved cash burn trajectory—suggests elevated near-term R&D spend ahead of inflection.

⚠ No revenue throughout entire period; clinical-stage risk concentration demands near-term data or partnership catalysts.

AI Insight: IMUX Ratio Trends

Immunic remains deeply unprofitable with negative ROE, ROA, and ROIC; minimal comparable data limits trend visibility.

• ROE deteriorated to -86.2% in Q1 2026 from -69.0% TTM; ROA worsened to -68.7% from -55.0% TTM.

• ROIC fell to -87.9% in Q1 2026 versus -72.5% TTM, indicating capital destruction accelerating.

⚠ Absence of quarterly profitability data Q3 2024–Q4 2025 obscures operational trajectory; verify cash burn rate and runway.

⚠ All return metrics negative; monitor for inflection toward breakeven or clinical trial milestones that could reverse losses.

Get alerted when IMUX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IMMUNIC, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IMUX

abrdn plc
$9.2M8,243,941 sh
BVF INC/IL
$8.5M7,652,972 sh
Avidity Partners Management LP
$6.4M669,941 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.7M5,138,316 sh
Soleus Capital Management, L.P.
$5.0M4,500,000 sh
Laurion Capital Management LP
$4.3M3,882,162 sh
MILLENNIUM MANAGEMENT LLC
$4.2M3,779,922 sh
MORGAN STANLEY
$3.7M3,288,540 sh
Nantahala Capital Management, LLC
$2.8M2,506,491 sh
683 Capital Management, LLC
$2.7M2,450,000 sh

Fund	Value	Shares
abrdn plc	$9.2M	8,243,941
BVF INC/IL	$8.5M	7,652,972
Avidity Partners Management LP	$6.4M	669,941
VANGUARD CAPITAL MANAGEMENT LLC	$5.7M	5,138,316
Soleus Capital Management, L.P.	$5.0M	4,500,000
Laurion Capital Management LP	$4.3M	3,882,162
MILLENNIUM MANAGEMENT LLC	$4.2M	3,779,922
MORGAN STANLEY	$3.7M	3,288,540
Nantahala Capital Management, LLC	$2.8M	2,506,491
683 Capital Management, LLC	$2.7M	2,450,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IMUX on your watchlist

Track score changes the day IMMUNIC, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IMUX a good stock to buy?

13F Pro's AI-powered analysis of IMMUNIC, INC. (IMUX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMUX are available on the IMUX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IMUX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMUX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IMMUNIC, INC.'s investment landscape.